Back to top

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$14.43 USD


+0.38 (2.70%)

Updated Nov 30, 2023 04:00 PM ET

After-Market: $14.46 +0.03 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.96%
5Strong Sell2.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (64 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up

Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Insulet (PODD) to Report Q3 Earnings: What's in the Cards?

Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Elevance Health (ELV) Beats Q3 Earnings, Hikes '23 Profit View

Elevance Health's (ELV) Q3 results gain on growing medical customer base and strong pharmacy product revenues. Adjusted net income is currently projected to be more than $33.00 per share for 2023.

Tirthankar Chakraborty headshot

3 Solid Stocks to Buy for Superb Earnings Acceleration

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse

The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Best Momentum Stocks to Buy for October 11th

PBF, PRAX and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 11, 2023.

New Strong Buy Stocks for October 11th

PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.

Humana (HUM) Boosts Healthcare Choices for MA Members in Denver

Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.

Tirthankar Chakraborty headshot

4 Stocks That Exhibit Solid Earnings Acceleration

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $12.66, moving -0.78% from the previous trading session.

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $13.53, marking a +1.42% move from the previous day.